Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
36.14
+0.12 (0.33%)
At close: Oct 9, 2025, 4:00 PM EDT
36.50
+0.36 (1.00%)
After-hours: Oct 9, 2025, 7:38 PM EDT

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2016 - 2020
Cystic Fibrosis Franchise Revenue
811.37M826.21M
Log In
Log In
Log In
Upgrade
Evrysdi Revenue
215.26M224.43M
Log In
Log In
Log In
Upgrade
Tremfya Revenue
149.35M147.14M
Log In
Log In
Log In
Upgrade
Trelegy Revenue
147.65M146.92M
Log In
Log In
Log In
Upgrade
Tysabri Revenue
122.59M124.82M
Log In
Log In
Log In
Upgrade
Imbruvica Revenue
-131.09M
Log In
Log In
Log In
Upgrade
Xtandi Revenue
--
Log In
Log In
Log In
Upgrade
Promacta Revenue
--
Log In
Log In
Log In
Upgrade
Other Products Revenue
606.04M548.82M
Log In
Log In
Log In
Upgrade
Total Income from Financial Royalty Assets
2.18B2.15B
Log In
Log In
Log In
Upgrade
Revenue from Intangible Royalty Assets
--
Log In
Log In
Log In
Upgrade
Other Royalty Income
--
Log In
Log In
Log In
Upgrade
Other Royalty Income and Revenue
120.32M114.15M
Log In
Log In
Log In
Upgrade
Revenue (Other)
--224.43M
Log In
Log In
Log In
Upgrade
Revenue (Total)
-2.26B
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2016 - 2020
Portfolio Receipts
3.04B2.80B
Log In
Log In
Log In
Upgrade
Updated Aug 6, 2025. Data Source: Fiscal.ai.